PSMB1, a signature gene in MP2, was identified as a therapeutic target in CRC, where the FDA‐approved drug Kinetin enhances PSMB1‐mediated oncoprotein degradation, effectively suppressing CRC progression in pre‐clinical models.81 Here, PSMB1 is linked to colorectal carcinoma.